Extensively Drug-Resistant Tuberculosis
"Extensively Drug-Resistant Tuberculosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
|Extensively Drug-Resistant Tuberculosis
- Extensively Drug-Resistant Tuberculosis
- Extensively Drug Resistant Tuberculosis
- Extremely Drug-Resistant Tuberculosis
- Drug-Resistant Tuberculoses, Extremely
- Drug-Resistant Tuberculosis, Extremely
- Extremely Drug Resistant Tuberculosis
- Extremely Drug-Resistant Tuberculoses
- Tuberculoses, Extremely Drug-Resistant
- Tuberculosis, Extremely Drug-Resistant
- Tuberculosis, Extremely Drug Resistant
- Tuberculosis, Extensively Drug-Resistant
- Drug-Resistant Tuberculoses, Extensively
- Drug-Resistant Tuberculosis, Extensively
- Extensively Drug-Resistant Tuberculoses
- Tuberculoses, Extensively Drug-Resistant
- Tuberculosis, Extensively Drug Resistant
Below are MeSH descriptors whose meaning is more general than "Extensively Drug-Resistant Tuberculosis".
Below are MeSH descriptors whose meaning is more specific than "Extensively Drug-Resistant Tuberculosis".
This graph shows the total number of publications written about "Extensively Drug-Resistant Tuberculosis" by people in this website by year, and whether "Extensively Drug-Resistant Tuberculosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Extensively Drug-Resistant Tuberculosis" by people in Profiles.
Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis. 2017 07; 17(7):707-715.
Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis. 2015 Jun; 21(6):977-83.
Diagnosis of Drug Resistance to Fluoroquinolones, Amikacin, Capreomycin, Kanamycin and Ethambutol with Genotype MTBDRsl Assay: a Meta-Analysis. Ann Clin Lab Sci. 2015; 45(5):533-44.
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013 Mar; 19(3):416-24.
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012 Oct 20; 380(9851):1406-17.
Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011 Jun 01; 57(2):146-52.
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010 Oct 19; 153(8):516-22.
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010 May 22; 375(9728):1798-807.